Depending on your insurer and health benefit plan, pharmacogenetic testing may be covered as an optional benefit, or reimbursed under your Healthcare Spending Account (HSA) for those who have this as part of their plan. If you will be submitting to your private insurance plan to have the cost of the test reimbursed, most insurers require that the test be ordered (by writing a prescription for the test) by a licensed prescriber (physician, nurse practitioner, or pharmacist who is licensed to prescribe medications.)

Inagene Personalized Insights™ is designed for anyone who is interested in understanding which drugs are likely to work best to treat their pain, mental health or a number of other conditions. Personalized Insights™ is also useful for people interested in knowing whether cannabis may be a good treatment option for them (please note the evidence for cannabis recommendations are currently preliminary). Even for those who currently do not take any medication, pharmacogenetics testing may be helpful as a proactive measure by finding out which medications would work best for you based on your genetics.

Unlike other genetic tests, Inagene Personalized Insights™ is uniquely focused on providing the most comprehensive test to support optimal treatment of pain and mental health conditions, as well as many other conditions. Personalized Insights™ also includes evaluation of cannabis options (please note the evidence for cannabis recommendations is currently preliminary). Inagene also tests for more genes and variants than any other Pharmacogenetics test on the Canadian market with the fastest turn around time.

 Inagene uses its own lab to process all results and is CLIA certified (stands for the Clinical Laboratory Improvement Amendments). CLIA's mandate is to ensure quality laboratory testing by ensuring pharmacogenetic labs meet quality control and accuracy standards that certify the results are accurate and the test does what it is designed to do.

DISCLOSURE:

This test is a medication-compatibility assessment, focused in the area of pain management. It provides personalized medication and dosing recommendations based on an individual’s genetic profile.

Test results should be considered in the context of other clinical variables and interpreted with the help of a medical professional. Additional genetic testing by sequencing might uncover other functional variations that you may carry that also affect the medication response but were not detected in this analysis. Genetic testing is accurate; however, some variability or inaccuracies can occur. Inagene tests all samples twice, to mitigate inaccuracy.

Research in this field is ongoing and new research may mean that the interpretation of the test results may change over time.

The Personalized Insights™ test targets genetic variations in the following genes: ABCB1, ADRB2, ATIC, BDNF, CACNA1B, CNIH3, CNR1, CNR1, COMT, CREB1, CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7, DRD2/ANKK1, EPHX1, FAAH, FKBP5, GABRG2, GIRK2/KCNJ6, GNB3, GP1BA, GRIK4, GSTP1, HLA-A, HLA-B, HTR1A, HTR2A, HTR2C, KCNG2, LTC4S, MC4R, MTHFR, MTRR, NRG1, OPRD1, OPRM1, PTGS1, PTGS2, RGMA, SCN1A, SCN9A, SLCO1B1, TNFA, TRPV1, UGT1A4, UGT2B7, UGH2B15, UMPS, as well as genomic regions not known to be associated a single gene.